ADC Therapeutics SA (ADCT) Tops Q1 EPS by 18c

ADC Therapeutics SA (NYSE: ADCT) reported Q1 EPS of ($0.22), $0.18 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $23.03 million versus the consensus estimate of $17.89 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• Amer Sports Inc. (AS) PT Lowered to $42 at Truist, but 'Momentum continues to surge in a tough macro'
• Palo Alto Networks (PANW) PT Raised to $390 at UBS, Neutral Rating Maintained
• UBS Reiterates Buy Rating on Gap, Inc. (GAP), Says Earnings Could Be a High-Volatility Event